|
Synonyms: LY-2439821 | LY2439821 | Taltz®
ixekizumab is an approved drug (FDA & EMA (2016))
Compound class:
Antibody
Comment: Ixekizumab binds to IL-17A and blocks its action.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A protein BLAST search using the variable region of the heavy chain of ixekizumab identifies this as sequence 118 from patent US7838638 [1]. In this patent binding affinity data for human IL-17 is provided for several antibody clones, but it does not specify which was chosen as ixekizumab, although mAbs 126, 121 and 104 did undergo additional experimental investigations. |
| Immunopharmacology Comments |
| Ixekizumab is an effective treatment option for psoriasis [3-4], with potential for patients with an inadequate response to anti-TNF therapies [2]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Psoriatic arthritis |
Disease Ontology:
DOID:9008 |
Phase 3 clinical candidate for PsA (see NCT02349295). | 10 |
| Psoriasis |
Disease Ontology:
DOID:8893 |
Approved therapeutic for psoriasis and plaque psoriasis. | |
